Table 2.
Proportional hazards models of inflammatory markers at baseline and risk (hazard ratio, HR) of exacerbation (all exacerbations, and virus‐induced exacerbations)
| Any exacerbation (n=22) | Virus pos. exacerbation (n=15) | |||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| FeNO >25 ppb | 3.1 (1.2‐7.8) | .015 | 3.4 (1.1‐10.4) | .033 |
| Sputum eosinophils >1% | 4.1 (1.2‐13.8) | .024 | 7.6 (1.6‐35.2) | .010 |
| Blood eosinophils >150 (×109 cells/L) | 1.2 (0.5‐2.9) | .720 | 1.0 (0.3‐3.0) | .941 |
| Atopy (positive SPT) | 0.5 (0.2‐1.2) | .129 | 0.6 (0.2‐1.6) | .269 |
| IgE >150 (×103 IU/L) | 1.3 (0.5‐3.3) | .648 | 1.4 (0.4‐4.5) | .555 |
Each HR in the table represents a regression model adjusted for ICS dose, smoking status, ACQ score and % predicted FEV1 at baseline.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.